**Selected for Doody's Core Titles (R) 2024 with "Essential Purchase" designation in Infectious Disease**
From the latest vaccination evidence, recommendations, and protocols . . . to new vaccine development and the use of vaccines in reducing disease, Plotkin's Vaccines, 8th Edition, covers every aspect of vaccination. Now completely revised and updated from cover to cover, this award-winning text continues to provide reliable information from global authorities, offering a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin's Vaccines is a must-have reference for current, authoritative information in this fast-moving field.
Contains all-new chapters on COVID-19, vaccine hesitancy, and non-specific effects of vaccines, as well as significantly revised content on new vaccine technologies such as mRNA vaccines, emerging vaccines, and technologies to improve immunization
Presents exciting new data on evolution of adjuvants across the centuries, dengue vaccines, human papillomavirus vaccines, respiratory syncytial virus vaccines, tuberculosis vaccines, and zoster vaccines
Provides up-to-date, authoritative information on vaccine production, available preparations, efficacy and safety, and recommendations for vaccine use, with rationales and data on the impact of vaccination programs on morbidity and mortality
Provides complete coverage of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues
Keeps you up to date with information on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies
Covers vaccine-preventable diseases, vaccine science, and licensed vaccine products, as well as product technologies and global regulatory and public health issues
Analyzes the cost-benefit and cost-effectiveness of different vaccine options
Helps you clearly visualize concepts and objective data through an abundance of tables and figures
Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices
Rezensionen / Stimmen
"This book covers the history, immunology, innovative technology, and public health impacts of vaccines, and includes chapters dedicated to each of the commonly used vaccines. Moreover, the title includes a companion ebook that contains late-breaking information on topics such as Mpox, not contained within the print version. This eighth edition is an update to the previous version, published in 2017, which was prior to the widespread use of mRNA vaccines and the SARS-CoV-2 pandemic." - (c)Doody's Review Service, 2023, Bradford Becken, MD (University of Nebraska Medical Center) Doody's Score: 5 Stars!
Auflage
Sprache
Verlagsort
Zielgruppe
Illustrationen
Maße
Höhe: 279 mm
Breite: 228 mm
Dicke: 67 mm
Gewicht
ISBN-13
978-0-323-79058-1 (9780323790581)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Autor*in
Professor of Medicine and Pediatrics, and Global Health, Emory University; Associate Director, Emory Vaccine Center, Atlanta GA; Bill & Melinda Gates Foundation, Seattle, WA; Former Director, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Chief, Division of Infectious Diseases, Director, Vaccine Education Center, The Children's Hospital of Philadelphia; Professor of Pediatrics, Maurice R. Hilleman Professor of Vaccinology, Perelman School of Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Professor of Pediatrics Emerita, USA
SECTION I General Aspects of Vaccination
1. A Short History of Vaccination
2. Vaccine Immunology
3. Non-specific Effects of Vaccines
4. Correlates of Protection
5. The Vaccine Industry
6. Vaccine Manufacturing
7. Evolution of Adjuvants Across the Centuries
8. Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States
9. Passive Immunization
SECTION II Licenced Vaccines and Vaccines in Development
10. General Immunization Practices
11. Human Adenovirus Vaccines
12. Anthrax Vaccines
13. Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI)
14. Cancer Vaccines
15. Cholera Vaccines
16. Combination Vaccines
17. Coronavirus Vaccines
18. Cytomegalovirus Vaccines
19. Dengue Vaccines
20. Vaccines Against Diarrhea Caused by Noncholera Bacteria
21. Diphtheria Toxoid
22. Ebola Vaccines
23. Nonpolio Enteroviruses
24. Epstein-Barr Virus Vaccines
25. Haemophilus Influenzae Type b Vaccines
26. Hepatitis A Vaccines
27. Hepatitis B Vaccines
28. Hepatitis C Vaccines
29. Hepatitis E Vaccines
30. Herpes Simplex Virus Vaccines
31. Human Immunodeficiency Virus Vaccines
32. Human Papillomavirus Vaccines
33. Inactivated and Recombinant Influenza Vaccines
34. Influenza Vaccine-Live
35. Japanese Encephalitis Vaccines
36. Lyme Disease Vaccines-the Journey Continues
37. Malaria Vaccines
38. Measles Vaccines
39. Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines
40. Meningococcal Vaccines Directed at Capsular Group B
41. Mumps Vaccines
42. Noninfectious Disease Vaccines
43. Norovirus
44. Parasitic Disease Vaccines
45. Pertussis Vaccines
46. Plague Vaccines
47. Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines
48. Pneumococcal Polysaccharide Vaccines
49. Poliovirus Vaccine-Inactivated
50. Poliovirus Vaccine-Live
51. Lyssaviruses and Rabies Vaccines
52. Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies
53. Rotavirus Vaccines
54. Rubella Vaccines
55. Smallpox and Vaccinia
56. Staphylococcus aureus Vaccines
57. Streptococcus Group A Vaccines
58. Streptococcus Group B Vaccines
59. Tetanus Toxoid
60. Tickborne Encephalitis Vaccines
61. Tuberculosis Vaccines
62. Typhoid Fever Vaccines
63. Varicella Vaccines
64. Yellow Fever Vaccine
65. Zika Virus Vaccines
66. Zoster Vaccines
SECTION III New Technologies
67. Technologies for Making New Vaccines
68. Genetic-Based Vaccine Vectors
69. Technologies to Improve Immunization
SECTION IV Vaccination of Special Groups
70. Vaccination of Immunocompromised Hosts
71. Vaccines for International Travel
72. Vaccines for Healthcare Personnel
73. Vaccination of Pregnant Women
SECTION V Public Health and Regulatory Issues
74. Immunization in the United States
75. Immunization in Europe
76. Immunization and Vaccine-Preventable Diseases in the Asia-Pacific Region
77. Immunization in Low- and Middle-Income Countries
78. Community Protection
79. Economic Analyses of Vaccine Policies
80. Regulation and Testing of Vaccines in the US
81. Regulation of Vaccines in Europe
82. Regulation of Vaccines in Low- and Middle-Income Countries
83. Vaccine Safety
84. Vaccine Hesitancy and Behavioral Factors Associated With Vaccine Uptake
85. Legal Issues
86. Ethics
ONLINE ONLY
87. Vaccines to Prevent Mpox
APPENDIX
Websites and Applications for Mobile Devices With Information About Immunization
